Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 24;11(10):dmm036236.
doi: 10.1242/dmm.036236.

Immune regulation of metastasis: mechanistic insights and therapeutic opportunities

Olga S Blomberg  1 , Lorenzo Spagnuolo  1 , Karin E de Visser  2
Affiliations
Review

Immune regulation of metastasis: mechanistic insights and therapeutic opportunities

Olga S Blomberg et al. Dis Model Mech. .

Abstract

Metastatic disease is the leading cause of death in cancer patients. Metastasis formation involves a cascade of events for which the underlying mechanisms are still poorly understood. During the metastatic cascade, cancer cells tightly interact with the immune system and they influence each other, both in the tumor microenvironment and systemically. The crosstalk between cancer and immune cells adds another layer of complexity to our understanding of metastasis formation, but at the same time opens new therapeutic opportunities for cancer patients. The intensifying development of immunotherapeutic strategies calls for a better understanding of immune regulation of metastasis in order to maximize the therapeutic benefit for patients with metastatic disease. In this Review and accompanying poster, we describe the main mechanisms of immune regulation of metastasis that have been reported to date, and present promising immunotherapeutic options that are currently available, or may become so in the near future, to tackle metastasis.

Keywords: (Pre-)metastatic niche; Immunotherapy; Inflammation; Metastasis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Acuff H. B., Carter K. J., Fingleton B., Gorden D. L. and Matrisian L. M. (2006). Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res. 66, 259-266. 10.1158/0008-5472.CAN-05-2502 - DOI - PMC - PubMed
    1. Ahmadzadeh M. and Rosenberg S. A. (2005). IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients. Blood 107, 2409-2414. 10.1182/blood-2005-06-2399 - DOI - PMC - PubMed
    1. Alexander W. (2016). The checkpoint immunotherapy revolution. Pharm. Ther. 41, 185-191. - PMC - PubMed
    1. Alitalo K., Tammela T. and Petrova T. V. (2005). Lymphangiogenesis in development and human disease. Nature 438, 946-953. 10.1038/nature04480 - DOI - PubMed
    1. Almand B., Resser J. R., Lindman B., Nadaf S., Clark J. I., Kwon E. D., Carbone D. P. and Gabrilovich D. I. (2000). Clinical significance of defective dendritic cell differentiation in cancer clinical significance of defective dendritic cell differentiation. Clin. Cancer Res. 6, 1755-1766. - PubMed

Publication types